Australia's InhaleRx rises as manufacturing begins for cancer pain trial

Nexalis Therapeutics

03/07/2025 05:31

** InhaleRx IRX.AX rises 2.6% to A$0.04, highest since June 27

** Medical devices maker starts manufacturing its lead investigational product, IRX-211, for phase 2 of breakthrough cancer pain clinical trial

** About 537,948 shares traded, 1.6x the 30-day avg

** IRX gains 14.3% YTD

 (Reporting by Jasmeen Ara Shaikh in Bengaluru)

 ((JasmeenAraIslam.Shaikh@thomsonreuters.com;))